This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16:343–356.e3. https://doi.org/10.1016/j.cgh.2017.06.016.
Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13:3–10. https://doi.org/10.1016/j.autrev.2013.06.004.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18:2179–2191.e6. https://doi.org/10.1016/j.cgh.2020.01.008.
Sands BE, Peyrin-Biroulet L, Loftus EV et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215–1226. https://doi.org/10.1056/NEJMoa1905725.
Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214. https://doi.org/10.1056/NEJMoa1900750.
Panaccione R, Danese S, Sandborn WJ et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020;52:1658–1675. https://doi.org/10.1111/apt.16119.
Welty M, Mesana L, Padhiar A et al. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin. 2020;36:595–606. https://doi.org/10.1080/03007995.2020.1716701.
Koder S, Repnik K, Ferkolj I et al. Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn’s disease patients. Pharmacogenomics. 2015;16:191–204. https://doi.org/10.2217/pgs.14.172.
Niess JH, Klaus J, Stephani J et al. NOD2 polymorphism predicts response to treatment in Crohn’s disease–first steps to a personalized therapy. Dig Dis Sci. 2012;57:879–886. https://doi.org/10.1007/s10620-011-1977-3.
Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207–211. https://doi.org/10.1038/ng1954.
Sazonovs A, Kennedy NA, Moutsianas L et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with crohn’s disease. Gastroenterology. 2020;158:189–199. https://doi.org/10.1053/j.gastro.2019.09.041.
Liu M, Degner J, Davis JW et al. Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS ONE. 2018;13:e0195325. https://doi.org/10.1371/journal.pone.0195325.
Mahajna H, Ben-Horin S. Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. Curr Opin Pharmacol. 2020;55:132–140. https://doi.org/10.1016/j.coph.2020.10.011.
Yilmaz B, Juillerat P, Øyås O et al. Microbial network disturbances in relapsing refractory Crohn’s disease. Nat Med. 2019;25:323–336. https://doi.org/10.1038/s41591-018-0308-z.
Magnusson MK, Strid H, Sapnara M et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis. 2016;10:943–952. https://doi.org/10.1093/ecco-jcc/jjw051.
Zhou Y, Xu ZZ, He Y et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018. https://doi.org/10.1128/mSystems.00188-17.
Dovrolis N, Michalopoulos G, Theodoropoulos GE et al. The interplay between mucosal microbiota composition and host gene-expression is linked with infliximab response in inflammatory bowel diseases. Microorganisms. 2020. https://doi.org/10.3390/microorganisms8030438.
Ananthakrishnan AN, Luo C, Yajnik V et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe. 2017;21:603-610.e3. https://doi.org/10.1016/j.chom.2017.04.010.
Amiot A, Filippi J, Abitbol V et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. 2020;51:1039–1046. https://doi.org/10.1111/apt.15717.
Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–1201. https://doi.org/10.1053/j.gastro.2011.06.054.
Christensen B, Hanauer SB, Erlich J et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15:1557-1564.e1. https://doi.org/10.1016/j.cgh.2017.02.016.
Li K, Marano C, Zhang H et al. Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.08.037.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
A profile of Rahul S. Dalal is available at https://doi.org/10.1007/s10620-021-06853-2.
About this article
Cite this article
Dalal, R.S., Ananthakrishnan, A.N., Hamilton, M.J. et al. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. Dig Dis Sci 66, 733–737 (2021). https://doi.org/10.1007/s10620-021-06852-3
- Inflammatory bowel diseases
- Ulcerative colitis